Clinical Trials Logo

Clinical Trial Summary

This is an investigator-initiated, proof-of-concept, randomised, double-blind, placebo-controlled, single-centre phase II study aiming to evaluate the efficacy, safety and tolerability of self-administered subcutaneous 120 µg dasiglucagon with an investigational trial device (i.e. a multi-dose reusable pen) for the treatment of postprandial hypoglycaemia after Roux-en-Y gastric bypass (RYGB) surgery. The study is divided into an in-patient and out-patient part. The primary aim of the study is to compare the effects of self-administered 120 µg dasiglucagon versus placebo on continuous glucose monitoring (CGM)-assessed time spent in hypoglycaemia in RYGB-operated individuals in an out-patient setting.


Clinical Trial Description

Study design: Before inclusion in the study, the participants will complete a screening visit and a blinded 14-day continuous glucose monitoring (CGM) run-in period to ascertain a regular occurrence of postprandial hypoglycaemia (IG <3.9 mmol/l, ≥3 times/week). After enrolment in the study, the participants will wear a CGM for the entirety of the study period (apart from the four weeks before the follow-up visit). Prior to the first mixed meal test (MMT) during the in-patient part, the subjects will be randomised into one of four double-blinded treatment sequences consisting of an in-patient part (two MMTs) follow by a nine weeks out-patient part (two times four weeks per out-patient part with an interposed washout period of one week) and ended with a follow-up visit four weeks after out-patient part completion. During the in-patient part, the participants will undergo two separate MMTs, with a minimum of 7 days in-between, accompanied by one of the following double-blind, randomised, placebo-controlled crossover interventions: 1. Subcutaneous placebo self-administration 2. Subcutaneous 120 µg dasiglucagon self-administration The out-patient part is divided into two double-blinded, randomised, placebo-controlled crossover out-patient parts with of the following interventions: 1. Subcutaneous placebo self-administration 2. Subcutaneous 120 µg dasiglucagon self-administration ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04836273
Study type Interventional
Source University Hospital, Gentofte, Copenhagen
Contact
Status Completed
Phase Phase 2
Start date August 20, 2021
Completion date December 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT03984370 - Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass Phase 2
Completed NCT03200782 - Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study N/A
Recruiting NCT05036317 - Empagliflozin for the Treatment of Postprandial Hypoglycemia Phase 3
Active, not recruiting NCT05174507 - Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes Phase 2
Completed NCT04330196 - Effect of Postprandial Hyperinsulinaemic Hypoglycaemia on Driving Performance. N/A
Recruiting NCT04720859 - Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) N/A
Completed NCT05676385 - Glucose Response to a Formula for Patients at Risk of Hypoglycaemia N/A
Completed NCT05513404 - The Scottish Fruit Study N/A
Completed NCT01162499 - Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia N/A
Recruiting NCT05401578 - Canakinumab for the Treatment of Postprandial Hypoglycemia Phase 3